fda compounding glp-1 warning letters september 2025 issued 25 to telehealth companies for false and misleading claims about compounded products. Unlike FDA-approved drugs, these products have not been proven to be safe, effective, or of FDA to Restrict Ingredients Used
Description
Rocket-like launches created unprecedented demand, stressed supply chains, and caused payers world-wide to question their ability to pay for obesity treatment
Mujeres embarazadas, menores de 18 aos y personas con condiciones mdicas deben consultar a su doctor antes de consumir suplementos
This study is recruiting participants to test the effectiveness of CT-868, a new investigational medication for blood sugar management being tested in people with type 1 diabetes and obesity.
It will likely be the most powerful weight loss drug yet but that doesn't mean it's for everyone, experts say.
